Pfizer Inc. (PFE)

• Annual Data
• Quarterly Data

Pfizer Inc., common-size consolidated income statement

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Revenues
	Cost of sales
	Gross profit
	Selling, informational and administrative expenses
	Research and development expenses
	Amortization of intangible assets
	Restructuring charges and certain acquisition-related costs
	Operating income
	Interest income
	Interest expense
	Net interest expense
	Foreign currency loss related to Venezuela
	Royalty-related income
	Net gains on asset disposals
	Net gains recognized during the period on investments in equity securities
	Net realized losses on sales of investments in debt securities
	Income from collaborations, out-licensing arrangements and sales of compound/product rights
	Net periodic benefit credits other than service costs
	Certain legal matters, net
	Certain asset impairments
	Loss on sale and impairment on remeasurement of HIS net assets
	Business and legal entity alignment costs
	Net losses on early retirement of debt
	Other, net
	Other income (deductions), net
	Income from continuing operations before (provision) benefit for taxes on income
	(Provision) benefit for taxes on income
	Income from continuing operations
	Income (loss) from discontinued operations, net of tax
	Gain (loss) on disposal of discontinued operations, net of tax
	Discontinued operations, net of tax
	Net income before allocation to noncontrolling interests
	Net income attributable to noncontrolling interests
	Net income attributable to Pfizer Inc.
	Preferred stock dividends, net of tax
	Net income attributable to Pfizer Inc. common shareholders

Based on: 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29), 10-K (filing date: 2015-02-27).